S1PR1 and neoplasm: Fingolimod, an agonist of four S1PRs (including S1PR1, S1PR3, S1PR4, and S1PR5), induces receptor internalization and exerts antagonistic effects, which could markedly reduce the tumor load and abrogate the NF-κB/IL-6/STAT3/S1PR1 cascade [30].